美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Beta Bionics, Inc.

23.28

+0.23001.00%

成交量：2.03萬

成交額：47.19萬

市值：10.12億

市盈率：-4.11

高：23.28

開：23.28

低：23.28

收：23.05

52周最高：26.66

52周最低：8.89

股本：4,347.01萬

流通股本：2,373.52萬

量比：2.15

換手率：0.09%

股息：- -

股息率：- -

每股收益(TTM):-5.6597

每股收益(LYR):-8.6026

淨資產收益率：-81.35%

總資產收益率：-21.78%

市淨率：3.23

市盈率(LYR):-2.71

資料載入中...

總覽公司新聞公告

Beta Bionics, Inc.2025財年第二財季實現淨利潤-16.87百萬美元，同比減少16.67%

異動解讀 | Beta Bionics股價盤中大漲10.98%，Truist證券上調目標價

異動解讀 | 業績超預期，Beta Bionics盤後大漲6.07%

Beta Bionics Inc 報告截至 6 月 30 日的季度業績 - 收益摘要

Beta Bionics Inc 預計每股虧損 45 美分 - 財報前瞻

BUZZ--美國股票走勢-NIP Group、凱悅酒店、BioXcel Therapeutics

BUZZ-CMS 提出招標計劃變更後，糖尿病設備製造商業績下滑

Beta Bionics(BBNX.US)獲Truist Securities首次覆蓋，給予買入評級, 目標價26.00美元。

Beta Bionics獲Wolfe Research首次覆蓋，給予優於大市評級, 目標價20.00美元。

Beta Bionics Inc 預計每股虧損 48 美分 - 財報前瞻

Beta Bionics, Inc.2024財年實現淨利潤-54.76百萬美元，同比減少190.50%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BBNX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBNX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBNX\",,,,,undefined,":{"symbol":"BBNX","market":"US","secType":"STK","nameCN":"Beta Bionics, Inc.","latestPrice":23.28,"timestamp":1758288781646,"preClose":23.05,"halted":0,"volume":20276,"delay":0,"floatShares":23735244,"shares":43470125,"eps":-5.659705,"marketStatus":"交易中","change":0.23,"latestTime":"09-19 09:33:26 EDT","open":23.28,"high":23.28,"low":23.28,"amount":471935.76146,"amplitude":0,"askPrice":23.35,"askSize":6,"bidPrice":22.87,"bidSize":88,"shortable":3,"etf":0,"ttmEps":-5.659705,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1758312000000},"marketStatusCode":2,"adr":0,"listingDate":1738213200000,"exchange":"NASDAQ","adjPreClose":23.05,"postHourTrading":{"tag":"盘后","latestPrice":23.05,"preClose":23.05,"latestTime":"17:32 EDT","volume":1805,"amount":41605.42,"timestamp":1758231153601},"volumeRatio":2.15186},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBNX\",,,,,undefined,":{"symbol":"BBNX","floatShares":23735244,"roa":"-21.78%","roe":"-81.35%","lyrEps":-8.602584,"volumeRatio":2.15186,"shares":43470125,"dividePrice":0,"high":23.28,"amplitude":0,"preClose":23.05,"low":23.28,"week52Low":8.89,"pbRate":"3.23","psRate":"14.49","week52High":26.66,"institutionHeld":0,"latestPrice":23.28,"committee":0.87234,"eps":-5.659705,"divideRate":0,"volume":20276,"delay":0,"ttmEps":-5.659705,"open":23.28,"prevYearClose":17,"prevWeekClose":26.41,"prevMonthClose":18.84,"prevQuarterClose":14.56,"fiveDayClose":26.41,"twentyDayClose":16.89,"sixtyDayClose":14.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBNX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"BBNX","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"盤後","type":"earning","dateTimestamp":1753761600000,"reportTimeType":"post","actualEps":-0.39},{"market":"US","date":"2025-05-06","symbol":"BBNX","fiscalQuarterEnding":"2025/03","expectedEps":-0.51,"name":null,"time":"盤後","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"post","actualEps":-0.52},{"market":"US","date":"2025-03-25","symbol":"BBNX","fiscalQuarterEnding":"2024/12","expectedEps":-0.42,"name":null,"time":"盤後","type":"earning","dateTimestamp":1742875200000,"reportTimeType":"post","actualEps":-1.82}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBNX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBNX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4444,"buy":0.3333,"hold":0.2222,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":9,"updateTime":1750132800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBNX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBNX","date":"2025-09-18","current":-14.156597,"percent":0.1875,"low":-18.401318,"twenty":-13.754592,"median":-10.046222,"eighty":-8.660901,"high":-3.90273,"avg":-11.020373,"sd":3.005672,"marketCap":1004594588},"quantilePoints":[{"date":"2025-01-31","current":-18.262207,"twenty":-16.058067,"median":-12.751858,"eighty":-7.442381,"marketCap":1013479428},{"date":"2025-02-07","current":-18.125788,"twenty":-18.207639,"median":-17.701026,"eighty":-14.679009,"marketCap":1005908733},{"date":"2025-02-14","current":-16.797439,"twenty":-18.139689,"median":-17.569735,"eighty":-16.871579,"marketCap":932190666},{"date":"2025-02-21","current":-16.117818,"twenty":-18.053192,"median":-17.39983,"eighty":-16.806707,"marketCap":894474446},{"date":"2025-02-28","current":-15.376414,"twenty":-17.738096,"median":-16.901699,"eighty":-15.527784,"marketCap":853329479},{"date":"2025-03-07","current":-13.754592,"twenty":-17.625341,"median":-16.797439,"eighty":-14.919215,"marketCap":763324863},{"date":"2025-03-14","current":-10.843036,"twenty":-17.540388,"median":-16.156433,"eighty":-12.952405,"marketCap":601745147},{"date":"2025-03-21","current":-12.117325,"twenty":-17.418365,"median":-15.88613,"eighty":-12.19996,"marketCap":672463060},{"date":"2025-03-28","current":-10.030495,"twenty":-17.316422,"median":-15.090664,"eighty":-11.612243,"marketCap":549229802},{"date":"2025-04-04","current":-8.526317,"twenty":-16.978156,"median":-13.955389,"eighty":-11.224551,"marketCap":466867006},{"date":"2025-04-11","current":-8.462983,"twenty":-16.936452,"median":-12.789848,"eighty":-9.75816,"marketCap":463399099},{"date":"2025-04-17","current":-8.660901,"twenty":-16.843777,"median":-12.343221,"eighty":-9.270489,"marketCap":474236309},{"date":"2025-04-25","current":-8.755902,"twenty":-16.843777,"median":-12.117325,"eighty":-8.660901,"marketCap":479438170},{"date":"2025-05-02","current":-8.819236,"twenty":-16.797439,"median":-11.630778,"eighty":-8.660901,"marketCap":482906077},{"date":"2025-05-09","current":-9.109566,"twenty":-16.202771,"median":-11.468596,"eighty":-8.660901,"marketCap":646442149},{"date":"2025-05-16","current":-8.41306,"twenty":-16.195048,"median":-11.020664,"eighty":-8.526317,"marketCap":597015989},{"date":"2025-05-23","current":-9.476148,"twenty":-16.117818,"median":-10.030495,"eighty":-8.550067,"marketCap":672455918},{"date":"2025-05-30","current":-9.384503,"twenty":-15.951002,"median":-9.677769,"eighty":-8.619734,"marketCap":665952476},{"date":"2025-06-06","current":-11.944468,"twenty":-15.890764,"median":-10.161718,"eighty":-8.656151,"marketCap":847615293},{"date":"2025-06-13","current":-11.90781,"twenty":-15.527784,"median":-10.843036,"eighty":-8.663027,"marketCap":845013916},{"date":"2025-06-20","current":-10.863051,"twenty":-15.401128,"median":-10.973025,"eighty":-8.671464,"marketCap":770874676},{"date":"2025-06-27","current":-9.158444,"twenty":-15.033515,"median":-10.853044,"eighty":-8.690985,"marketCap":649910652},{"date":"2025-07-03","current":-8.260318,"twenty":-14.588672,"median":-10.413035,"eighty":-8.668829,"marketCap":586176919},{"date":"2025-07-11","current":-8.284756,"twenty":-14.14074,"median":-9.690076,"eighty":-8.535817,"marketCap":587911170},{"date":"2025-07-18","current":-8.043423,"twenty":-13.87507,"median":-9.628891,"eighty":-8.433029,"marketCap":570785439},{"date":"2025-07-25","current":-8.816301,"twenty":-13.38389,"median":-9.506697,"eighty":-8.433029,"marketCap":625631134},{"date":"2025-08-01","current":-10.285126,"twenty":-12.797445,"median":-9.491423,"eighty":-8.48456,"marketCap":729863398},{"date":"2025-08-08","current":-9.243749,"twenty":-12.637058,"median":-9.506697,"eighty":-8.519369,"marketCap":655964186},{"date":"2025-08-15","current":-10.23612,"twenty":-12.367549,"median":-9.430326,"eighty":-8.524348,"marketCap":726385788},{"date":"2025-08-22","current":-10.346383,"twenty":-12.210773,"median":-9.506697,"eighty":-8.53478,"marketCap":734210411},{"date":"2025-08-29","current":-11.461269,"twenty":-12.163662,"median":-9.628891,"eighty":-8.548511,"marketCap":813326038},{"date":"2025-09-05","current":-12.312748,"twenty":-12.179108,"median":-9.681286,"eighty":-8.567484,"marketCap":873749512},{"date":"2025-09-12","current":-15.522638,"twenty":-12.446687,"median":-9.727683,"eighty":-8.641901,"marketCap":1101532967},{"date":"2025-09-18","current":-14.156597,"twenty":-13.754592,"median":-10.046222,"eighty":-8.660901,"marketCap":1004594588}],"updateTime":1758282876175},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBNX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2556846826","title":"Beta Bionics, Inc.2025財年第二財季實現淨利潤-16.87百萬美元，同比減少16.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556846826","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556846826?lang=zh_tw&edition=fundamental","pubTime":"2025-08-03 00:01","pubTimestamp":1754150479,"startTime":"0","endTime":"0","summary":"8月3日，Beta Bionics, Inc.公布财报，公告显示公司2025财年第二财季净利润为-16.87百万美元，同比减少16.67%；其中营业收入为23.24百万美元，同比增加54.42%，每股基本收益为-0.39美元。从资产负债表来看，Beta Bionics, Inc.总负债28.34百万美元，其中短期债务1.52百万美元，资产负债比为0.12，流动比率为0.15。机构评级：截至2025年8月3日，当前有9家机构对Beta Bionics, Inc.目标价做出预测，其中目标均价为23.67美元，其中最低目标价为17.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250803000154a6cf783e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250803000154a6cf783e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBNX"],"gpt_icon":0},{"id":"1103250329","title":"異動解讀 | Beta Bionics股價盤中大漲10.98%，Truist證券上調目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1103250329","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103250329?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 22:46","pubTimestamp":1753886790,"startTime":"0","endTime":"0","summary":"周三盘中，Beta Bionics股价大幅上涨10.98%，引起投资者广泛关注。推动Beta Bionics股价上涨的主要因素是华尔街分析师的积极评价。据悉，Truist Securities分析师于当日将Beta Bionics的目标价从18美元上调至21美元，这一举动显著提振了投资者信心。分析人士认为，Truist Securities上调目标价反映了对Beta Bionics公司未来发展前景的看好。作为一家专注于开发人工胰腺系统的医疗科技公司，Beta Bionics在糖尿病管理领域具有创新优势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBNX"],"gpt_icon":0},{"id":"1100799004","title":"異動解讀 | 業績超預期，Beta Bionics盤後大漲6.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100799004","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100799004?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 05:06","pubTimestamp":1753823186,"startTime":"0","endTime":"0","summary":"周二盘后，Beta Bionics, Inc.股价大涨6.07%，主要受益于公司发布的季度业绩报告好于市场预期。根据公司公布的财报，截至6月30日的季度调整后每股亏损为39美分，优于分析师平均预期的45美分亏损。值得注意的是，尽管Beta Bionics股价在本季度下跌了3.9%，但华尔街分析师对公司前景仍保持乐观。目前，分析师对该公司股票的平均评级为\"买入\"，12个月目标价中位数为26.00美元，较最新收盘价13.99美元高出约46.2%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBNX"],"gpt_icon":0},{"id":"2555061237","title":"Beta Bionics Inc 報告截至 6 月 30 日的季度業績 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2555061237","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555061237?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 05:01","pubTimestamp":1753822898,"startTime":"0","endTime":"0","summary":"Beta Bionics Inc 报告截至 6 月 30 日的季度业绩 - 收益摘要Beta Bionics Inc BBNX.OQ 公布了截至 6 月 30 日的季度调整后每股亏损 39 美分。Beta Bionics Inc公布的本季度每股收益为亏损39美分。该公司当季亏损 1687 万美元。Beta Bionics Inc 的股价本季度下跌了 3.9%。华尔街对 Beta Bionics 公司 12 个月目标价的中位数为 26.00 美元，比上次收盘价 13.99 美元高出约 46.2%。本摘要由 LSEG 7 月 29 日 09:01 p.m. UTC 调制解调器器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nL4T3TQ26L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX","BK4082"],"gpt_icon":0},{"id":"2554677794","title":"Beta Bionics Inc  預計每股虧損 45 美分 - 財報前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2554677794","media":"路透中文","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554677794?lang=zh_tw&edition=fundamental","pubTime":"2025-07-26 04:07","pubTimestamp":1753474029,"startTime":"0","endTime":"0","summary":"Beta Bionics Inc  预计每股亏损 45 美分 - 财报前瞻Beta Bionics Inc BBNX.OQ BBNX.O 预计将于7月29日公布截至2025年6月30日的财报。根据LSEG的数据，9位分析师的平均预期是，这家总部位于加利福尼亚州欧文市的公司预计将实现1968.4万美元的营收。LSEG 的分析师平均预计 Beta Bionics 公司每股亏损 45 美分。华尔街对 Beta Bionics 公司 12 个月目标价的中位数为 26.00 美元，比上次收盘价 14.43 美元高出约 44.5%。7月25日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nL4T3TM1J3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX"],"gpt_icon":0},{"id":"2548900430","title":"BUZZ--美國股票走勢-NIP Group、凱悅酒店、BioXcel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2548900430","media":"路透中文","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548900430?lang=zh_tw&edition=fundamental","pubTime":"2025-07-01 21:13","pubTimestamp":1751375632,"startTime":"0","endTime":"0","summary":"nL4N3SY0TC ** Trade Desk Inc < TTD.O  >:BUZZ - 在花旗银行上调 PT 后上涨 nL4N3SY0UP ** Zscaler Inc < ZS.O  >:BUZZ - 在出售 15 亿美元可转债后下跌 nL6N3SY0HS ** Ormat Technologies Inc < ORA.N  >:BUZZ - 由于无碳电力需求上升，Jefferies 上调 Ormat Technologies 的 PT nL4N3SY0UG ** Nektar Therapeutics Inc < NKTR.O  >:BUZZ - 1亿美元股票出售后走低 nL6N3SY0K8 ** Nike Inc < NKE.N  >:BUZZ - Argus Research将耐克公司的评级提升至 \"买入\"，认为其市场主导地位仍将持续。nL4N3RM0VN ** BioXcel Therapeutics Inc < BTAI.O  >:BUZZ - 因精神分裂症药物试验推荐结果良好而上涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nL4T3SY0ZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0612318385.USD","TSYW.SI","HL","LU1066051811.HKD","WYNN","LU1674673691.USD","NEM","SG9999004303.SGD","IE0009355771.USD","H","LU2237443549.SGD","AMC","ABT","BK4503","DXCM","LU1691799644.USD","SG","TTD","LVS","BK4009","CDE","IE00B894F039.SGD","BK4527","NIPG","BK4141","CTAS","BTAI","ZS","DYN","LU2063271972.USD","LU2112291526.USD","AU","LU0648001328.SGD","TNDM","BK4511","LU1720051108.HKD","ORA","SYF","BBNX","LU0278409577.USD"],"gpt_icon":1},{"id":"2548064870","title":"BUZZ-CMS 提出招標計劃變更後，糖尿病設備製造商業績下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2548064870","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548064870?lang=zh_tw&edition=fundamental","pubTime":"2025-07-01 20:02","pubTimestamp":1751371376,"startTime":"0","endTime":"0","summary":"BUZZ-CMS 提出招标计划变更后，糖尿病设备制造商业绩下滑7月1日 -  ** 糖尿病设备制造商 DexCom DXCM.O 和 Tandem Diabetes Care TNDM.O 的股价盘前分别下跌近 4 ** DXCM 下跌3.8%，报84美元，TNDM下跌3.9%，报17.92美元 ** 美国医疗保险与医疗补助服务中心周一晚些时候提议修改竞争性招标计划，旨在降低糖尿病 患者购买胰岛素泵、连续血糖监测仪 和其他设备的共付额。** 摩根大通称，这些变化将影响到生产 CGM 的雅培ABT.N和 DXCM，以及 胰岛素泵制造商 TNDM 和 Beta Bionics BBNX.O。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nL4S3SY0VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ23171101.USD","LU0868494617.USD","LU0122379950.USD","LU2125909247.SGD","LU2133065610.SGD","BK4588","BK4534","IE0009355771.USD","BK4585","LU1057294990.SGD","LU1989763690.USD","LU2211815571.USD","SG9999002232.USD","LU2433249047.HKD","LU2125909593.SGD","SG9999004303.SGD","BK4566","TNDM","LU1323610961.USD","IE00BFTCPJ56.SGD","LU1914381329.SGD","BK4568","BK4533","LU1691799644.USD","SG9999002224.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BMPRXR70.SGD","LU1989763427.SGD","LU0354030511.USD","LU1061106388.HKD","BK4082","LU2468319806.SGD","BBNX","ABT","LU1721429741.USD","DXCM","LU0266013472.USD","LU2089984988.USD","BK4548","LU0170899867.USD","LU1923622614.USD","LU2237957811.SGD","BK4592","LU2237957902.USD","LU0354030438.USD","IE00BMPRXN33.USD","BK4581","IE00BJT1NW94.SGD","LU0234572021.USD"],"gpt_icon":0},{"id":"2544046746","title":"Beta Bionics(BBNX.US)獲Truist Securities首次覆蓋，給予買入評級, 目標價26.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2544046746","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544046746?lang=zh_tw&edition=fundamental","pubTime":"2025-06-17 00:20","pubTimestamp":1750090806,"startTime":"0","endTime":"0","summary":"Beta Bionics(BBNX.US)获Truist Securities首次覆盖，给予买入评级, 目标价26.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/17002051100004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBNX"],"gpt_icon":0},{"id":"2539427938","title":"Beta Bionics獲Wolfe Research首次覆蓋，給予優於大市評級, 目標價20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2539427938","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539427938?lang=zh_tw&edition=fundamental","pubTime":"2025-05-30 23:44","pubTimestamp":1748619866,"startTime":"0","endTime":"0","summary":"Beta Bionics(BBNX.US)获Wolfe Research首次覆盖，给予优于大市评级, 目标价20.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025053023493495086e76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025053023493495086e76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBNX"],"gpt_icon":0},{"id":"2532803800","title":"Beta Bionics Inc  預計每股虧損 48 美分 - 財報前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2532803800","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532803800?lang=zh_tw&edition=fundamental","pubTime":"2025-05-03 06:48","pubTimestamp":1746226088,"startTime":"0","endTime":"0","summary":"Beta Bionics Inc  预计每股亏损 48 美分 - 财报前瞻Beta Bionics Inc BBNX.OQ BBNX.O 预计将于5月6日公布截至2025年3月31日的财报。LSEG 分析师对 Beta Bionics Inc 的平均预期是每股亏损 48 美分。华尔街对 Beta Bionics Inc 的 12 个月目标价中位数为 26.00 美元，高于其最新收盘价 11.14 美元。5月2日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nL4S3RA2IC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX"],"gpt_icon":0},{"id":"2522385216","title":"Beta Bionics, Inc.2024財年實現淨利潤-54.76百萬美元，同比減少190.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522385216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522385216?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 23:00","pubTimestamp":1743001244,"startTime":"0","endTime":"0","summary":"3月26日，Beta Bionics, Inc.公布财报，公告显示公司2024财年净利润为-54.76百万美元，同比减少190.50%；其中营业收入为65.12百万美元，同比增加679.88%，每股基本收益为-8.60美元。从资产负债表来看，Beta Bionics, Inc.总负债73.63百万美元，其中短期债务1.53百万美元，资产负债比为0.03，流动比率为0.07。机构评级：截至2025年3月26日，当前有7家机构对Beta Bionics, Inc.目标价做出预测，其中目标均价为26.14美元，其中最低目标价为18.00美元，最高目标价为31.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250326230057a442bfc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250326230057a442bfc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBNX"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}